Yoland Antill

Cancer Specialist, lover of life

[Yoland Antill @AntillYoland]

I’m trekking the Larapinta Trail to raise money for WomenCan! Please support me in whatever way you can. https://t.co/vfnCnBmW2P #WomenCanLarapinta2022 via @raisely

[Yoland Antill @AntillYoland]

@bensolomon1 @PeterMacCC Here’s wishing for a MUCH more normal 2021

[Yoland Antill @AntillYoland]

Australia is on track to be the first country to eradicate cervical cancer | The New Daily https://t.co/Hbkg5z1Nsa

[Yoland Antill @AntillYoland]

A fantastic read- couldn’t put it down

[Petronella McGovern @PetronellaMcGov]

It’s publication day for my psychological thriller, Six Minutes, with many thanks to the fabulous team @AllenAndUnwin!

[Yoland Antill @AntillYoland]

@kylie_gorringe That’s brilliant news-congratulations

[Yoland Antill @AntillYoland]

Vale to an amazing man https://t.co/9q8DVBwIak

[Yoland Antill @AntillYoland]

ASCO 2019
https://t.co/txZjeqCPLS

[Ian Davis (Bluesky @profiand) @Prof_IanD]

#ENZAMET:

Slides available here on @ANZUPtrials web site: https://t.co/uDr9YlcoDW

Paper here: https://t.co/GGC3Vl6Tsu @NEJM

Thanks to the cast of thousands @ChrisSweens1 @TrialsCentre @CDNCancerTrials @cancertrials_ie @DanaFarber☝️and our selfless patients.

#ASCO19

[NEJM @NEJM]

The ENZAMET (Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic #ProstateCancer) trial investigated the effects of adding enzalutamide to first-line treatment that included testosterone suppression with or without early docetaxel. #ASCO19

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Nice session on rare breast cancer subtypes this morning @asco. Good: ER+ tubular, mucinous; ER neg with interesting chromosomal abnormalities include medullary, mucoepidermoid, secretory, adenoid cystic. Not so good: micropapillary.

[Yoland Antill @AntillYoland]

Still need to think of that pMMR tumours- how can we make them immune sensitive???

[Linda Mileshkin @LindaMileshkin]

Excited to hear @yolandantill presenting the results of our @ANZGOG study of Durvalumab in advanced endometrial cancers showing a RR of 43% in MMR deficient cancers but minimal activity in MMR proficient cancers @PeterMacCC

[Martin Stockler @MartinStockler]

Yoland Antill’s PHAEDRA phase 2 trial of durvalumab in metastatic endometrial cancer.
Objective tumour responses in
15/35 MMR deficient,
1/36 MMR proficient.
Great Team effort w @anzgog @TrialsCentre @PeeySei @LindaMileshkin @redheadkristy #ASCO19 #AussieOnPodium